Genovis receives order worth approximately 1 million euros from global pharmaceutical company
Genovis AB, a leading provider of innovative enzyme technologies, today announced it has received an order with a total value of approximately EUR 1 million (SEK 11 million) from a global pharmaceutical company. The order includes material and related services connected to one of Genovis’ proprietary antibody conjugation technology platforms.
Genovis’ technology platform will be used as part of the manufacturing process to produce material for a novel drug candidate currently in preclinical development, and is expected to remain part of the manufacturing process if the program progresses into clinical development. Manufacturing of the reagents required to support the project will begin immediately, and delivery is expected to be completed no later than early 2026.
“We are proud to support this important program and pleased that our technology platforms continue to enable the development of innovative biopharmaceuticals,” says Fredrik Olsson, CEO of Genovis.
This order represents a significant milestone for Genovis’ bioconjugation business and highlights the growing importance of the company’s technologies in the field of next-generation therapeutics.
